Valence 로고
인기
로그인
Loading data for TLSIW — first visit, this takes a few seconds.

관심목록에 추가

TriSalus Life Sciences In...

NasdaqGM: TLSIW · 실시간 가격 · USD
0.56
+0.00 (0.00%)
종가 기준: Aug 14, 2026, 3:25 PM

TriSalus Life Sciences Inc. (TLSIW) Stock Price, Analysis & Data

0.00%

데이터 없음

매수호가n/a
시가총액n/a
매출 (ttm)45.08M
순이익 (ttm)-57.25M
베타0.43
EPS (ttm)n/a
P/E (ttm)n/a
선행 P/En/a
P/B (ttm)2.68
P/S (ttm)n/a
Earnings Daten/a
매도호가n/a
거래량70
평균 거래량 (20일)4,082
시가1.11
전일 종가0.56
일중 범위0.56 - 0.56
52주 범위0.44 - 2.19
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

TLSIW 소개

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures...

[더 보기]
산업
섹터
IPO 일자 Feb 9, 2021
직원 수 102
상장 거래소 NasdaqGM
티커 TLSIW
웹사이트 https://trisaluslifesci.com
전체 기업 정보

재무 실적

2025년 TriSalus Life Sciences의 매출은 45.15M로, 전년 29.43M 대비 53.41% 증가했습니다. 순이익은 -39.23M로, 30.56% 증가했습니다.

재무제표
news image

1일 전 · MarketBeat

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

TriSalus Life Sciences (NASDAQ:TLSI) outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity’s Global Growth Conference, with management emphasizing...

news image

1주 전 · MarketBeat

TriSalus Life Sciences Q2 Earnings Call Highlights

TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increas...

news image

1주 전 · GuruFocus.com

TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...

TriSalus Life Sciences Inc (TLSI) reiterates full-year guidance as reimbursement breakthrough in office-based labs and robust clinical pipeline position the company for accelerated back-half growth.

news image

3개월 전 · GuruFocus.com

TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...

TriSalus Life Sciences Inc (TLSI) navigates commercial growth and FDA delays while showcasing improved margins and robust clinical data.

news image

3개월 전 · MarketBeat

TriSalus Life Sciences Q1 Earnings Call Highlights

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delaye...

2 페이지 중 1